Bristol Myers’ immunotherapy combo nets two new approvalsnews2025-04-11T17:36:43+00:00April 11th, 2025|Endpoints News|
CDMOs anticipate inspection bottlenecks after FDA firingsnews2025-04-11T13:18:17+00:00April 11th, 2025|Endpoints News|
FDA is reversing return-to-office mandate for some workersnews2025-04-10T22:10:17+00:00April 10th, 2025|Endpoints News|
Biotech CEOs to Cassidy: We’re already seeing the effects of FDA’s staff cutsnews2025-04-10T13:32:52+00:00April 10th, 2025|Endpoints News|
Firings of HHS’ probationary workers can proceed, appeals court saysnews2025-04-09T19:19:23+00:00April 9th, 2025|Endpoints News|
ICER outlines ways to increase GLP-1 access as costs risenews2025-04-09T15:46:48+00:00April 9th, 2025|Endpoints News|
House panel mulls ways to boost struggling biosimilar marketnews2025-04-08T19:18:53+00:00April 8th, 2025|Endpoints News|
Kennedy’s FDA cuts raise questions about ‘trigger’ for user feesnews2025-04-08T17:21:13+00:00April 8th, 2025|Endpoints News|
Rare disease hub at CDER and CBER faces new reality with staff crunchnews2025-04-07T19:30:50+00:00April 7th, 2025|Endpoints News|
‘This is self-inflicted’: Leerink’s David Risinger on the market shock and hits to biopharmanews2025-04-07T17:34:32+00:00April 7th, 2025|Endpoints News|
